Shanghai Kehua Bio-engineering (002022.SZ): The hepatitis C virus (HCV) nucleic acid detection kit (PCR-fluorescence method) has obtained a medical device registration certificate.
Kehua Bio (002022.SZ) announced that its subsidiary, Suzhou Tianlong Biotechnology Co., Ltd., has recently...
Shanghai Kehua Bio-engineering (002022.SZ) announced that its holding subsidiary, Suzhou Tianlong Bio-technology Co., Ltd., has received a medical device registration certificate (in vitro diagnostic reagent) issued by the National Medical Products Administration. The product involved is the "Hepatitis C Virus (HCV) Nucleic Acid Detection Kit (PCR-fluorescence method)". This product is used for quantitatively detecting Hepatitis C Virus nucleic acid (RNA) in human serum or plasma samples.
Related Articles
China Securities Co.,Ltd.: Brain-Computer Interface Upgraded to a 15th Five-Year Plan Industrial Strategy; Upstream, Midstream, and Downstream Collaborate to Build a New Ecosystem of Human-Machine Integration
Russian court rules that Rio Tinto plc Sponsored ADR (RIO.US) must pay RUSAL (00468) approximately US$1.3 billion in damages; Mongolian OT copper mine interests may face enforcement
UBS Group AG: Maintains "Neutral" rating on Tesla, Inc. (TSLA.US), target price $385. AI narrative dominates the stock's pricing logic.
China Securities Co.,Ltd.: Brain-Computer Interface Upgraded to a 15th Five-Year Plan Industrial Strategy; Upstream, Midstream, and Downstream Collaborate to Build a New Ecosystem of Human-Machine Integration
Russian court rules that Rio Tinto plc Sponsored ADR (RIO.US) must pay RUSAL (00468) approximately US$1.3 billion in damages; Mongolian OT copper mine interests may face enforcement
UBS Group AG: Maintains "Neutral" rating on Tesla, Inc. (TSLA.US), target price $385. AI narrative dominates the stock's pricing logic.
